

ASX RELEASE

5 August 2020

Change of Director's Interest Notice – Appendix 3Y: Dr John Lambert

Appendix 3Y Change of Director's Interest Notice for Dr. John Lambert is attached.

This ASX announcement was approved and authorised for release by the Company Secretary of Amplia Therapeutics Limited.

- End -

For further information:

Andrew J. Cooke
Company Secretary
andrew@ampliatx.com
www.ampliatx.com

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Amplia Therapeutics Limited
ABN	16 165 160 841

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	John Nicholas Lambert
Date of last notice	12 February 2020

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	LLAC Investments Pty Ltd <Ralph Super Fund A/C> of which Dr. Lambert is a Director and beneficiary. Parallax Consulting Pty Ltd of which Dr. Lambert is a Director and a beneficiary.
Date of change	4 August 2020

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

<p>No. of securities held prior to change</p>	<p>Direct: 1,200,000 Options (i) Exercise Price: \$0.165 (ii) 4 years vesting (accelerated upon completion of Phase 1 trial); (iii) Fully vested in a change of control; (iv) Expire 24 June 2024.</p> <p>Indirect: 100,000 fully paid shares 50,000 Options – Exercise Price \$0.15 Expiry Date 30 June 2022</p> <p>750,000 Options – Exercise Price \$0.60 Expiry Date 31 August 2022 (issued 31 August 2018). Note – disclosure of these options was inadvertently omitted from the Appendix 3X for Dr. Lambert lodged with the ASX on 12 February 2020.</p>
<p>Class</p>	<p>Fully Paid Ordinary Shares</p>
<p>Number acquired</p>	<p>120,000 Shares</p>
<p>Number disposed</p>	<p>Nil</p>
<p>Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation</p>	<p>\$0.10 per share – Retail Entitlement Offer</p>
<p>No. of securities held after change</p>	<p>Direct: 1,200,000 Options (v) Exercise Price: \$0.165 (vi) 4 years vesting (accelerated upon completion of Phase 1 trial); (vii) Fully vested in a change of control; (viii) Expire 24 June 2024.</p> <p>Indirect: 220,000 fully paid shares 50,000 Options – Exercise Price \$0.15 Expiry Date 30 June 2022</p> <p>750,000 Options – Exercise Price \$0.60 Expiry Date 31 August 2022</p>
<p>Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<p>Participation in Retail Entitlement Offer</p>

+ See chapter 19 for defined terms.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Nil
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
Interest acquired	
Interest disposed	
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

5 August 2020

+ See chapter 19 for defined terms.